Primary vs. second primary cT1-T2 oral squamous cell carcinoma: comparing the outcomes
Noëmi Ramirez-Guanche(Catholic University of America), Vincent Vander Poorten(KU Leuven), Annouschka Laenen(Statistics Belgium), Sandra Nuyts(Cancer Institute (WIA)), Davide Di Santo(KU Leuven), Paul M. Clément(Universitair Ziekenhuis Leuven), Fien Jaeken(Catholic University of America), Jeroen Meulemans(KU Leuven)
Cited by 1
Related Papers
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
|Journal of Clinical Oncology|2009|573
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
|The Lancet Oncology|2016|504